Discovery may lead to development of safer immunosuppressants

Immunosuppressive treatment is necessary to prevent rejection of an organ after transplant and has great potential for treating chronic inflammatory diseases. However, currently available immunosuppressant drugs can pose serious health risks, restricting their long-term use. Now, new research findings may lead to the development of immunosuppressant drugs that have fewer adverse side effects. The study, published by Cell Press in the March 13th issue of the journal Molecular Cell, reveals detailed information about how drugs commonly used to prevent transplant rejection interact with their target.

If you want to include this story in your blog, copy and paste this formatted text:

<p><a href="http://www.physorg.com/news156084308.html">Discovery may lead to development of safer immunosuppressants</a></p> <p>Immunosuppressive treatment is necessary to prevent rejection of an organ after transplant and has great potential for treating chronic inflammatory diseases. However, currently available immunosuppressant drugs can pose serious health risks, restricting their long-term use. Now, new research findings may lead to the development of immunosuppressant drugs that have fewer adverse side effects. The study, published by Cell Press in the March 13th issue of the journal <I>Molecular Cell,</I> reveals detailed information about how drugs commonly used to prevent transplant rejection interact with their target.</p>